Blood test reveals amyloid plaques; cannabinoids’ weak case for treating mental disorders

Blood test might rival PET scan for brain amyloidosis By M. Alexander Otto   A blood test that measures the plasma ratio of amyloid-beta 42 peptide to amyloid-beta peptide 40 can accurately screen cognitively normal individuals for brain amyloidosis.   You can take the MDedge Podcasts survey by clicking here.   Other news:   Evidence lacking for using cannabinoids to treat mental disorders Scant evidence exists to recommend medical cannabinoids to patients with depressive disorders, anxiety, or other mental disorders.   SUSTAIN 10: Glycemic control, weight loss better with semaglutide than liraglutide Once-weekly treatment with subcutaneous semaglutide yielded greater reductions in HbA1c and body weight than once-daily liraglutide.   Severe hypoglycemia, poor glycemic control fuel fracture risk in older patients with type 2 diabetes The association between severe hypoglycemia, poor glycemic control, and fracture risk seems to be stronger in men than in postmenopausal women.   Demeaning patient behavior takes emotional toll on physicians Deciding how or whether to respond was often dictated by the level of support from colleagues, a professional responsibility to peers.   You can contact the MDedge Daily Medical News by emailing us at [email protected] or following us on Twitter at @MDedgeTweets